Niagen Bioscience (FRA:OCD1) Moat Score: 4/10 (As of Jul. 29, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:OCD1 Niagen Bioscience Inc FRA:OCD1
67 GF Score
Price €2.58
GF Value €3.98
Valuation Possible Value Trap
! 2 Warning Signs
View Full Analysis

What is Niagen Bioscience Moat Score?

Niagen Bioscience FRA:OCD1 67 Moat Score is 4 as of Jul. 29, 2026. GuruFocus rates FRA:OCD1 with a GF Score™ of 67/100 and a GF Value™ of €3.98 (Possible Value Trap). The stock has 2 warning signs investors should review. Among 1,393 Biotechnology companies, Niagen Bioscience ranks better than 88.8% on this metric.

Niagen Bioscience has the Moat Score of 4, which implies that the company might have Narrow Moat - Discernible but modest moat.

Niagen Bioscience has Narrow Moat: Niagen Bioscience Inc has a discernible but modest moat due to its niche market presence and some valuable intellectual property. However, it lacks strong brand strength, significant customer switching costs, and durable cost advantages, limiting its competitive edge.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Niagen Bioscience might have Narrow Moat - Discernible but modest moat.

Niagen Bioscience  (FRA:OCD1) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Niagen Bioscience Moat Score Related Terms

FRA:OCD1 vs LCTX, IFRX, VRXA: Moat Score Comparison

For the Biotechnology subindustry, Niagen Bioscience's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Niagen Bioscience Moat Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Niagen Bioscience's Moat Score distribution charts can be found below:

* The bar in red indicates where Niagen Bioscience's Moat Score falls into.


FRA:OCD1
67GF Score
Niagen Bioscience Inc FRA:OCD1
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 4 mean?
Niagen Bioscience (FRA:OCD1) has a Moat Score of 4 as of Jul. 29, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, Niagen Bioscience ranks #156 out of 1393 companies in the Biotechnology industry, placing it in the top 11.2%.
Is Niagen Bioscience's Moat Score too high?
Niagen Bioscience's current Moat Score is 4. The Biotechnology industry median Moat Score is 2.00. Niagen Bioscience's value of 4 is 100% above this industry median. Based on the distribution chart, Niagen Bioscience ranks #156 out of 1393 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Niagen Bioscience has a GF Score™ of 67/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Niagen Bioscience's Moat Score compare to LCTX and IFRX?
According to the Biotechnology industry distribution chart, Niagen Bioscience ranks #156 out of 1393 companies for Moat Score. This places Niagen Bioscience in the top 11% of its industry — outperforming the majority of peers. The industry median Moat Score is 2.00. Niagen Bioscience's value of 4 is 100% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Biotechnology company?
The median Moat Score among Biotechnology companies is 2.00, based on 1,393 companies in the industry. Companies in the top quartile (top 25%) have a Moat Score significantly above this median, while those in the bottom quartile fall well below. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Niagen Bioscience's current Moat Score of 4 is 100% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. For the Biotechnology industry, the median Moat Score is 2.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Niagen Bioscience's current Moat Score is 4. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Niagen Bioscience stock overvalued right now?
Based on GuruFocus' analysis, Niagen Bioscience (FRA:OCD1) is currently considered Possible Value Trap. The stock's GF Value™ is €3.98, compared to a current price of €2.58 — trading 35.2% below its estimated fair value. The current Moat Score is 4 and 100% above the Biotechnology industry median of 2.00. Niagen Bioscience's overall GF Score™ is 67/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For Niagen Bioscience (FRA:OCD1), the current Moat Score is 4 as of Jul. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Niagen Bioscience (FRA:OCD1) Overvalued in 2026?

Based on GuruFocus' analysis, Niagen Bioscience stock appears to be undervalued. The current stock price of €2.58 is trading 35.2% below its estimated GF Value™ of €3.98. GuruFocus considers Niagen Bioscience to be Possible Value Trap.

Key valuation signals for FRA:OCD1:

  • Moat Score: 4
  • GF Value™: €3.98 vs. price of €2.58 (35.2% below fair value)
  • GF Score™: 67/100 with 2 warning signs
  • Industry Position: 100% above the Biotechnology median (#156 of 1393)

No single metric tells the full story. See the FRA:OCD1 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Niagen Bioscience Business Description

Other Exchanges NAGE:USAOCD1:Germany
Address 10900 Wilshire Boulevard, Suite 600, Los Angeles, CA, USA, 90024
Niagen Bioscience Inc is the leader in NAD+ (nicotinamide adenine dinucleotide) science and healthy-aging research. It is dedicated to advancing healthspan through precision science and innovative NAD+-boosting solutions. It is is clinically proven to increase NAD+ levels efficiently and effectively, and is the key ingredient powering our suite of Niagen brands.
67GF Score

Get the complete analysis for FRA:OCD1

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€2.58
Price
€3.98
GF Value